Background Currently, coronavirus disease-2019 (COVID-19) is continuously and rapidly circulating, resulting in serious and extensive effects on human health. Due to the absence of antiviral medicine for COVID-19 thus far, there is a desperate need to develop effective medicine. Traditional Chinese medicine (TCM) has been widely applied in the treatment of epidemic diseases in China, with the aim of achieving clinical efficacy and decreasing the use of antibiotics and glucocorticoids. The aim of this study was to evaluate the efficacy and safety of Baidu Jieduan granules in treating COVID-19. Methods/design This multicentre, open-label, randomized controlled trial will be conducted in 300 patients with COVID-19. The patients will be randomly (1:1) divided into a treatment group and a control group. All patients will receive standard therapy at the same time. Patients in the experimental group will receive Baidu Jieduan granule treatment twice a day for 14 days. The outcomes will be assessed at baseline and at 3, 5, 7 and 14 days after treatment initiation. The primary outcome will be the rate of symptom (fever, fatigue and coughing) recovery. Adverse events (AEs) will be monitored throughout the trial. Discussion The study will provide high-quality clinical evidence to support the efficacy and safety of Baidu Jieduan granules in the treatment of moderate COVID-19, and enrich the theory and practice of TCM in treating COVID-19. Trial registration Chinese Clinical Trial Registry ChiCTR2000029869 . Registered on 15 February 2020 Supplementary Information The online version contains supplementary material available at 10.1186/s13063-021-05418-y.
【저자키워드】 COVID-19, Randomized controlled trial, Baidu Jieduan granule, Efficacy and safety, 【초록키워드】 Randomized controlled trial, Treatment, coronavirus disease, Glucocorticoids, coronavirus, Trial, Open-label, fatigue, Traditional Chinese medicine, Antibiotics, Symptom, outcome, Moderate COVID-19, adverse events, Health, clinical, Fever, Patient, Controlled trial, multicentre, registry, TCM, Clinical efficacy, Standard therapy, epidemic disease, twice a day, Support, Adverse, Primary outcome, epidemic diseases, control group, supplementary material, experimental group, Chinese, treatment group, treatment initiation, circulating, clinical evidence, coughing, treating COVID-19, theory, antiviral medicine, Effect, effective, Baidu, event, Randomly, resulting, develop, evaluate, conducted, applied, absence, receive, 1:1, AEs, baseline, Granule, patients with COVID-19, use of antibiotics, 【제목키워드】 Treatment, Study protocol, Randomized, moderate, Controlled clinical trial, Chinese, Baidu, granules,